随着下游公司用商业贿赂手段销售药品万脉宁的行为被查处，常山药业也将被启动信用评价。 1月11日，据国家医保局公众号，上海市普陀区市场监督管理局在去年4月发现，上海海怡莱企业咨询管 理合伙企业（下称"上海海怡莱"）涉嫌实施商业贿赂。 智通财经记者 | 黄华 智通财经编辑 | 谢欣 上海海怡莱与上海泓健医药有限公司（下称"泓健医药"）于2023年1月签订协议，为泓健医药在上海销 售达肝素钠注射液（批准文号H20143110，商品名：万脉宁）提供市场推广和信息服务工作，包括市场 信息收集维护、开展学术会议、走访医生等。 期间，上海海怡莱向泓健医药承诺，其服务能够维持并增加万脉宁在上海的销量。经调查发现，上海海 怡莱为了推动上海市第一妇婴保健院相关医生多开具万脉宁，销售推广总监及股东袁某某承诺生殖免疫 科医生顾某，开药即可给予好处费。 经统计，2023年1月至12月期间，袁某通过个人微信转账支付4笔好处费，共计约3.5万元；对应时段 内，医生共开具万脉宁约1.83万支。上海海怡莱从泓健医药公司获取万脉宁2023年度市场推广和信息服 务的业务收入合计约86.87万元。 普陀区市场监督管理局认为，上海海怡莱所采用的手段构 ...

今日提示 ·国务院新闻办公室将于1月12日举行新闻发布会，介绍第六届亚洲沙滩运动会筹办情况。 ·第44届摩根大通医疗健康年会将于当地时间1月12日至15日举办，大会将成为展示临床数据、洽谈海外 合作的核心舞台。 ·ST柯利达1月12日开市起复牌，实际控制人拟变更。 ·ST新亚1月12日开市起停牌一天，13日开市起复牌并撤销其他风险警示，证券简称变更为"新亚制程"。 ·爱舍伦1月12日申购，代码920050，发行价15.98元/股，市盈率14.99倍，申购上限76.13万股，主营一次 性医用耗材。 上证精选 ○A股仍有上行空间 1月9日，上证指数成功站上4100点关口，创下2015年7月以来的新高，同时A股单日成交额第6次突破3 万亿元，春季行情正在向纵深展开。多家研究机构认为，A股仍有上行空间。 申万宏源证券认为，春季有利于做多的时间窗口连续不断：1月市场面临的重大风险扰动因素较少；2月 春节前反弹是A股胜率最高的日历特征之一，同时也是科技领域可能兑现重磅催化的窗口；3月政策层 面的催化可能更加丰富。在此背景下，春季行情演绎出风险偏好驱动的特征。现阶段，全部A股赚钱效 应指标仅略高于历史中位数，成长相对价值的 ...

格隆汇1月9日丨常山药业(300255.SZ)公布，近日收到通知，公司药品依诺肝素钠注射液在美国的新药 简略申请（简称ANDA，即美国仿制药申请）获得美国食品药品监督管理局（简称美国FDA）的批准。 依诺肝素钠注射液用于预防静脉血栓栓塞性疾病（预防静脉内血栓形成），特别是与骨科或普外手术有 关的血栓形成；治疗已形成的深静脉栓塞，伴或不伴有肺栓塞，临床症状不严重，不包括需要外科手术 或溶栓剂治疗的肺栓塞；与阿司匹林合用，治疗不稳定性心绞痛及非Q波心肌梗死；用于血液透析体外 循环中，防止血栓形成。 ...

公告显示，依诺肝素钠注射液用于预防静脉血栓栓塞性疾病(预防静脉内血栓形成)，特别是与骨科或普 外手术有关的血栓形成;治疗已形成的深静脉栓塞，伴或不伴有肺栓塞，临床症状不严重，不包括需要 外科手术或溶栓剂治疗的肺栓塞;与阿司匹林合用，治疗不稳定性心绞痛及非Q波心肌梗死;用于血液透 析体外循环中，防止血栓形成。 智通财经APP讯，常山药业(300255.SZ)公告，公司药品依诺肝素钠注射液在美国的新药简略申请(简称 ANDA，即美国仿制药申请)获得美国食品药品监督管理局(简称美国FDA)的批准。 ...

常山药业（300255）(300255.SZ)公告，公司药品依诺肝素钠注射液在美国的新药简略申请(简称 ANDA，即美国仿制药申请)获得美国食品药品监督管理局(简称美国FDA)的批准。 公告显示，依诺肝素钠注射液用于预防静脉血栓栓塞性疾病(预防静脉内血栓形成)，特别是与骨科或普 外手术有关的血栓形成;治疗已形成的深静脉栓塞，伴或不伴有肺栓塞，临床症状不严重，不包括需要 外科手术或溶栓剂治疗的肺栓塞;与阿司匹林合用，治疗不稳定性心绞痛及非Q波心肌梗死;用于血液透 析体外循环中，防止血栓形成。 ...

常山药业公告，公司药品依诺肝素钠注射液在美国的新药简略申请（ANDA）获得美国食品药品监督管 理局（FDA）批准。依诺肝素钠注射液用于预防静脉血栓栓塞性疾病，特别是与骨科或普外手术有关的 血栓形成；治疗已形成的深静脉栓塞，伴或不伴有肺栓塞；与阿司匹林合用，治疗不稳定性心绞痛及非 Q波心肌梗死；用于血液透析体外循环中，防止血栓形成。 ...

Core Viewpoint - The low molecular weight heparin (LMWH) market in China is experiencing steady growth, driven by advancements in medical technology and increasing clinical applications, with a projected market size of approximately 68.07 billion yuan in 2024 and 69.29 billion yuan in 2025 [1][5]. Group 1: Market Size and Structure - The LMWH market in China is expected to reach 68.07 billion yuan in 2024, with the following market share distribution: dalteparin sodium injection (15.47%), low molecular weight heparin calcium injection (7.01%), nadroparin calcium injection (18.22%), enoxaparin sodium injection (26.77%), and other LMWH preparations (32.54%) [1][5]. - By 2025, the market size is projected to be around 69.29 billion yuan, with similar distribution trends among the various LMWH products [1][5]. Group 2: Industry Development and Trends - The LMWH industry has evolved significantly since the discovery of heparin in the early 20th century, with key milestones including the commercialization of heparin in 1938 and the introduction of nadroparin in 1978 [3]. - The Chinese LMWH industry has undergone three stages: crude product export, industrial enhancement, and the establishment of a complete industrial chain [3]. - The global LMWH market is also growing, with a projected increase from 4.334 billion USD in 2020 to 5.876 billion USD in 2024, and an expected market size of 6.2 billion USD in 2025 [4]. Group 3: Production and Demand - The production of LMWH in China is on the rise, with an estimated output of 36,327 million doses in 2024, up from 17,367 million doses in 2020, and expected to exceed 40,000 million doses in 2025 [6][7]. - The demand for LMWH in China is projected to reach approximately 42,523 million doses by 2025, reflecting a growing need for these anticoagulants in clinical settings [5][6]. Group 4: Competitive Landscape - Major companies in the Chinese LMWH market include Jiuyuan Gene, Hongri Pharmaceutical, Chenxin Pharmaceutical, and others, with a concentration of production in eastern coastal regions such as Jiangsu, Shandong, and Guangdong [8]. - In 2024, the market share of imported LMWH products remains above 20%, with notable sales figures for domestic products, including 3.42 billion yuan for Sanofi's enoxaparin sodium injection and 4.12 billion yuan for Qilu Pharmaceutical's LMWH sodium injection [8][9]. Group 5: Technological Advancements - The production technology for LMWH has advanced significantly, moving from traditional chemical degradation methods to modern biotechnological approaches, enhancing product purity and reducing production costs [9][10]. - Future trends in the LMWH industry include a focus on high-efficiency, green, and intelligent production methods, as well as the development of customized LMWH products in response to the rise of personalized medicine [11][12].

Core Insights - The company has shown initial success in its strategic transformation, with a significant reduction in sales and management expenses leading to a narrowing of net profit loss by 37.98% year-on-year [1][2] Financial Performance - The company reported operating revenue of 492 million yuan, with a net profit attributable to shareholders of -29.09 million yuan, a year-on-year improvement of 37.98% [2] - The net cash flow from operating activities reached 173 million yuan, demonstrating strong cash collection capabilities despite a slight year-on-year decline of 13.95% [2] - The debt structure has improved, with a stable debt-to-asset ratio of 67% and long-term loans reduced to 4.358 billion yuan [2] Innovation Pipeline - The core product, Aibennate, has made significant progress in diabetes and weight loss indications, with its New Drug Application (NDA) for diabetes already accepted by the National Medical Products Administration [3] - Aibennate is expected to enter the market soon, targeting a global market exceeding 100 billion USD for weight loss drugs by 2030 [3] - The company is also advancing its second key product, CSCJC3456, an FGFR inhibitor, which is currently in Phase I clinical trials for advanced malignant tumors [3][4] Cost Management and International Expansion - The company has achieved cost reductions in its heparin business, with a self-supply rate of 65% for heparin crude products, leading to a 12% reduction in per-ton costs compared to external purchases [5] - The export revenue from heparin sodium injection has increased by 21% year-on-year, supported by registrations in countries like Tanzania and Belarus [5] - The company has established multiple national and provincial research platforms, with a total of 108 invention patents, enhancing its innovation and international competitiveness in the biopharmaceutical sector [5]

Economic Overview - As of August 18, 2025, nine districts in Shenzhen have reported their economic performance for the first half of the year, with Nanshan, Futian, Longgang, and Baoan each surpassing 250 billion yuan in GDP, collectively accounting for over 72.6% of the city's GDP [1][3] - Nanshan district, recognized as the "first district" in Guangdong's economy, approached 500 billion yuan in GDP, maintaining a significant lead over other districts [1][4] - The overall GDP of Shenzhen reached 18,322.26 billion yuan, with an average growth rate of 5.1% [3][6] District Performance - Nanshan's GDP for the first half of 2025 was 4980.06 billion yuan, with a growth rate of 4.8%, contributing over 30% to the city's tertiary industry value [4][6] - Futian district reported a GDP of 2953.15 billion yuan, with a notable growth rate of 7.9%, driven primarily by the financial sector, which saw a 16% increase in value added [7][6] - Longgang and Baoan districts had GDPs of 2809.67 billion yuan and 2560.22 billion yuan, respectively, with growth rates of 1.8% and 4.7% [7][6] Emerging Districts - The relatively new districts of Pingshan, Guangming, Dapeng, and Shenshan have shown impressive growth despite lower total GDP figures. Guangming's cross-border e-commerce exports surged by 834.16%, leading the city [2][12] - Dapeng district achieved a GDP growth of 8.7%, the highest among the reported districts, supported by its tourism sector [12][13] Industrial Development - Nanshan district's industrial sector is characterized by high-value "urban industry," attracting major companies like Siemens, which is establishing a high-end medical equipment manufacturing base [5][4] - The second and third industries in Baoan district are also evolving, with modern service industries accounting for 67.1% of its service sector [8][6] International Trade and Export - Pingshan district is focusing on expanding its international trade, particularly in the automotive and biopharmaceutical sectors, with significant growth in exports [11][10] - BYD's "Shenzhen No. 1" roll-on/roll-off ship recently exported over 6,800 electric vehicles, marking a significant milestone for local production [10][9] Investment and Projects - Dapeng district has attracted 46 new projects with an intended investment of 5.67 billion yuan, indicating a robust interest from external enterprises [13][12] - Guangming district is advancing its first cross-border e-commerce industrial park, aiming to enhance its global market reach [12][2]

Group 1 - Shenzhen's economic performance in the first half of 2025 shows significant growth, with four districts (Nanshan, Futian, Longgang, and Baoan) surpassing 250 billion yuan in GDP, collectively accounting for over 72.6% of the city's GDP [1][5] - Nanshan district, recognized as the "first district of Guangdong's economy," approached 500 billion yuan in GDP, maintaining its leading position, while Futian, Longgang, and Baoan followed with GDPs of 295.3 billion yuan, 280.9 billion yuan, and 256.0 billion yuan respectively [1][5] - Several districts, including Futian, Longhua, Pingshan, Yantian, and Dapeng, outperformed the city's average GDP growth rate of 5.1% in the first half of the year [1] Group 2 - Emerging districts like Pingshan, Guangming, Dapeng, and Shenshan, despite lower total GDP, exhibited impressive growth rates, with Guangming's cross-border e-commerce imports and exports soaring by 834.16%, ranking first in the city [2] - Dapeng New District attracted 46 projects with an intended investment of 5.67 billion yuan, marking a 21.4% increase in newly established business entities, the highest in the city [2][16] Group 3 - The 2025 CSDI Top 100 Districts list highlighted Shenzhen's dominance, with Nanshan, Futian, Baoan, and Longgang occupying four of the top five spots [4] - Nanshan's GDP for 2024 is projected to reach 950 billion yuan, with a significant contribution from the software and internet sectors, accounting for nearly 70% of the city's software industry [5] Group 4 - Futian district's GDP reached 295.3 billion yuan in the first half of the year, with a notable 7.9% year-on-year growth, driven primarily by the financial sector, which saw a 16.0% increase [7] - Longgang and Baoan ranked third and fourth in GDP, with Longgang's GDP at 280.9 billion yuan (1.8% growth) and Baoan's at 256.0 billion yuan (4.7% growth) [7] Group 5 - The transformation of Shenzhen as a leading industrial city is evident, with a focus on enhancing both manufacturing and service sectors [8] - Baoan district's modern service industry accounted for 67.1% of its service sector, with a significant growth in digital creative industries [8] Group 6 - The deepening internationalization of the automotive sector is highlighted by BYD's export of over 6,800 electric vehicles from the Shenshan area, marking a significant milestone in the region's economic development [10][12] - Pingshan district's GDP reached 65.1 billion yuan, with a focus on expanding its automotive and biopharmaceutical industries, showcasing its potential for international market expansion [14][15] Group 7 - Dapeng New District's GDP grew by 8.7% to 229.2 billion yuan, driven by its tourism sector, which is supported by multiple new coastal tourism projects [16][17] - The district's strategic location and policy support are expected to enhance its tourism and related industries significantly [16][17]